The drug and health products industry is boosting lobbying efforts amid a national sentiment to lower prescription drug prices, reports The New York Times.
Here are four statistics on pharma lobbying.
1. The drug and health products industry spent $78.14 million in the first quarter of this year to fund lobbying efforts, up 14 percent from the same period a year prior, according to Center for Responsive Politics data cited by The New York Times.
2. The insurance industry spent the second highest amount on lobbying this year among all industries at $40.16 million, according to Center for Responsive Politics data.
3. The drug and health products industry pays about 1,100 lobbyists, representing "more than two for each member of Congress," notes The New York Times.
4. The drug and health products industry spent more than $58 million during the 2016 election cycle, funding campaigns for Congress members, presidential candidates and other political causes, according to the Center for Responsive Politics. This total represents the biggest investment in the industry's history, marking a 20 percent increase from the 2012 election cycle, according to The New York Times.
To access Center for Responsive Politics' data, click here.
More articles on supply chain:
Supply chain tip of the day: Schedule daily huddles with surgical teams
Controversial bill addressing diabetes drug prices reaches Nevada governor's desk: 5 things to know
Marijuana-derived epilepsy drug nears FDA approval